News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accumetrics, Inc. Release: 8500+ Patient Trial Validates Association Between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012



10/26/2012 7:50:16 AM

MIAMI--(BUSINESS WIRE)--Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced the presentation of the 1-year results from the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) registry at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting. Study findings indicate a significant association between platelet reactivity and 12-month stent thrombosis, myocardial infarction, and death. ADAPT-DES had previously demonstrated an approximately four times greater rate of stent thrombosis at 30-days in patients with high residual platelet reactivity (HRPR), as measured by Accumetrics’ VerifyNow P2Y12 Test. This association continued through follow-up, as patients with HRPR demonstrated a 2.5 times greater rate of stent thrombosis at 1-year. The VerifyNow P2Y12 Test and VerifyNow PRUTest are used to measure a patient’s platelet reactivity and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavix® and Effient®).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES